RecruitingNot ApplicableNCT06542484

The Real-world Treatment Satisfaction by Gefapixiant in RCC

The Real-world Treatment Satisfaction by Gefapixiant in Patients with Refractory Chronic Cough in Terms of Cough Improvement and Taste Disturbance. (The RESTORE Study)

Sponsor

Nagoya City University

Enrollment

63 participants

Start Date

Dec 4, 2024

Study Type

INTERVENTIONAL

Conditions

chronic cough

Summary

Chronic cough has a high global prevalence and it is refractory to such treatments by approximately 20% of patients. Gafapixant is a P2X3 receptor antagonist that has demonstrated the reduction of cough in patients with refractory chronic cough(RCC). Taste disturbance is the most frequent adverse event by gefapixant (approximately 60-70%). Although gefapixant is well-tolerated even if taste disturbance has occurred, the impact of taste disturbance on cough-specific QoL remains to be unclear. Therefore, the investigator would like to evaluate factors related to treatment satisfaction by gefapixant in RCC patients. the investigator hypothesize that taste disturbance will be associated with the improvement of cough specific QoL and treatment satisfaction in RCC patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This real-world study examines how satisfied patients with refractory chronic cough (a persistent cough that has not responded to treatments targeting its cause) are with gefapixant, an approved medication that works by blocking certain nerve signals driving the cough reflex. One notable side effect of gefapixant is altered taste, and this study explores whether the degree of taste disturbance is linked to cough improvement and overall treatment satisfaction. Adults with a chronic cough lasting at least 8 weeks that has not responded to standard treatments, who have never or formerly smoked (with less than 20 pack-years), are eligible. Participation involves taking gefapixant as prescribed and completing questionnaires about cough severity, quality of life, taste changes, and treatment satisfaction at follow-up visits. This summary was generated by AI to help patients understand the study in plain language.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.